A Single and Multiple Ascending Dose study of AB-423 in in Healthy Volunteers

Trial Profile

A Single and Multiple Ascending Dose study of AB-423 in in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs AB 423 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 03 Oct 2017 According to an Arbutus Biopharma media release, data from this trial will be presented at The Liver Meeting 2017 organized by the American Association for the Study of Liver Diseases (AASLD) 2017.
    • 03 Aug 2017 According to an Arbutus Biopharma Corporation media release, top-line results from this trial are expected in the fourth quarter of 2017.
    • 31 Mar 2017 Status changed from planning to recruiting, as reported in an Arbutus Biopharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top